Radiation therapy in renal cell carcinoma

•Historically, the renal cell carcinoma (RCC) is considered a radioresistant tumor.•Radical surgery is the mainstay treatment approach.•Nowadays, hypofractionated radiotherapy (HRT) has gained a growing interest in RCC management.•Several topics, such as role, side effects and radioresponsiveness, n...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2018-08, Vol.128, p.82-87
Main Authors: De Felice, Francesca, Tombolini, Vincenzo
Format: Article
Language:English
Subjects:
Animals
Carcinoma, Renal Cell - radiotherapy
Ceramide
Dose Hypofractionation
Humans
kidney
Kidney Neoplasms - radiotherapy
Oligometastasis
Radioresistance
Radiosensitivity
Radiosurgery
Radiotherapy
Renal cell carcinoma
Stereotactic
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Historically, the renal cell carcinoma (RCC) is considered a radioresistant tumor.•Radical surgery is the mainstay treatment approach.•Nowadays, hypofractionated radiotherapy (HRT) has gained a growing interest in RCC management.•Several topics, such as role, side effects and radioresponsiveness, need to be clarified.•Based on early clinical trials, HRT seems to be a promising option in RCC management. Renal cell carcinoma (RCC) is classically regarded as extremely resistant to classical fractionated radiation therapy (RT). Nowadays, there is convincing data supporting RCC radiosensitivity to high fraction doses, which may represent an ideal issue for new treatment strategies in primary and oligometastatic RCC disease. This review discusses the role of RT in RCC and its potential therapeutic scenario focusing on the most interesting clinical trials.
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2018.06.002